Koninklijke Philips (NYSE:PHG – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.
Koninklijke Philips Stock Up 1.0%
PHG stock opened at $26.46 on Friday. Koninklijke Philips has a twelve month low of $21.48 and a twelve month high of $32.91. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.69. The stock has a market cap of $25.48 billion, a P/E ratio of 139.26, a PEG ratio of 0.72 and a beta of 0.75. The business’s 50-day moving average price is $24.03 and its 200-day moving average price is $24.97.
Koninklijke Philips (NYSE:PHG – Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The technology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.29 by $0.12. Koninklijke Philips had a return on equity of 11.95% and a net margin of 1.00%. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $4.35 billion. On average, equities research analysts forecast that Koninklijke Philips will post 1.63 EPS for the current year.
Hedge Funds Weigh In On Koninklijke Philips
About Koninklijke Philips
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
Featured Stories
- Five stocks we like better than Koninklijke Philips
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Why Teradyne’s 19% Rally Is Just Getting Started
- What Are Dividend Champions? How to Invest in the Champions
- Buy the Dip on 3 Overlooked Names With Major Potential
- What Are the U.K. Market Holidays? How to Invest and Trade
- Bitcoin and Dividends: A Winning Combo in These 3 ETFs
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.